Supreme Cannabis (SPRWF), unlike its peers (HMMJ) including CannTrust (CTST), HEXO (HEXO), and Cronos Group (CRON), hasn’t received much attention. So far, the stock has returned an impressive 76% this year. We’ll discuss analysts’ recommendations and target price for the next 12-month period.
The number of analysts covering Supreme Cannabis increased to six from five in February. Among the six analysts, two recommended a “strong buy” for the next 12-month period. Three analysts recommended a “buy,” which remained unchanged month-over-month. In March, one more analyst initiated coverage on Supreme Cannabis with a “hold” recommendation.
In March, none of the analysts recommended a “sell” or “strong sell.” The overall recommendation for Supreme Cannabis was a “buy.” Analysts are optimistic about the stock in March.
The consensus target price on Supreme Cannabis as of the time of this writing was 3.18 Canadian dollars, which was lower than 3.31 Canadian dollars in February. Supreme Cannabis closed at 2.2 Canadian dollars on March 20, which would leave an upside of nearly 43% if the current price converged with analysts’ target.